• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

ASAP Functionalized LbL Film for Localized Delivery of STAT3 siRNA and Oxaliplatin Combination to Treat Colon Cancer
ACS Applied Materials& InterfacesDOI: 10.1021/acsami.1c22166
Source: ACS Applied Materials and Interfaces - February 16, 2022 Category: Materials Science Authors: Leela Sai Lokesh Janardhanam, Sony Priyanka Bandi, and Venkata Vamsi Krishna Venuganti Source Type: research

CD44 expression enhances chemoresistance and implies occult micrometastases after conversion hepatectomy for initially unresectable colorectal liver metastases.
CONCLUSIONS: CD44 enhances chemoresistance in response to anti-cancer drugs (fluorouracil and oxaliplatin) in colon cancer cells. CD44 expression in liver metastases after chemotherapy implies the presence of occult micrometastases and is a worse prognostic factor in patients with conversion hepatectomy for initially unresectable colorectal liver metastases. PMID: 33042471 [PubMed]
Source: American Journal of Translational Research - October 13, 2020 Category: Research Tags: Am J Transl Res Source Type: research

microRNA ‐29b inhibits cell growth and promotes sensitivity to oxaliplatin in colon cancer by targeting FOLR1
AbstractThe present study was aimed to explore the functional role of microRNA (miR) ‐29b in colon cancer, as well as underlying mechanisms. Expressions of miR‐29b and folate receptor 1 (FOLR1) were measured in both human colon tumor samples and cell lines. Colon cancer cell lines SW480 and SW620 were transfected with miR‐29b mimic, antisense oligonucleotides (ASO)‐miR‐29b , small interfering (siRNA) against FOLR1 (si‐FOLR1), or corresponding negative controls (NCs), and then were incubated with or without oxaliplatin (L‐OHP). Thereafter, cell viability, cytotoxicity, cell apoptosis, and expression of FOLR1, ...
Source: BioFactors - October 16, 2019 Category: Biochemistry Authors: Qiang Fu, Jindai Zhang, Gaofeng Huang, Yonglei Zhang, Minghai Zhao, Yongchao Zhang, Jianguo Xie Tags: RESEARCH COMMUNICATION Source Type: research

Overexpression of CASC11 in ovarian squamous cell carcinoma mediates the development of cancer cell resistance to chemotherapy.
Abstract LncRNA CASC11 promotes gastric cancer and colon cancer. Our study analyzed the role of CASC11 in ovarian squamous cell carcinoma (OSCC). In the present study we showed that plasma CASC11 was upregulated in OSCC, and the upregulation of CASC11 distinguished OSCC patients from control group. Plasma levels of CASC11 were further increased after chemotherapy. Treatment with oxaliplatin, tetraplatin, cisplatin, and carboplatin mediated the upregulation of CASC11 in cells of OSCC cell line. In addition, overexpression of CASC11 led to increased cancer cell viability under oxaliplatin, tetraplatin, cisplatin, an...
Source: Gene - June 6, 2019 Category: Genetics & Stem Cells Authors: Shen F, Feng L, Zhou J, Zhang H, Xu Y, Jiang R, Zhang H, Chen Y Tags: Gene Source Type: research

A Study on Effect of Oxaliplatin in MicroRNA Expression in Human Colon Cancer
This study outlines the regulatory effects of oxaliplatin on miRNAs expression in colon cancer cells and correlates it with the changing microRNA expression with p53 and p73 expression status in cells. HCT116p53+/+ and HCT116p53-/- cells were exposed to oxaliplatin, and the cellular viability was determined by XTT. p73 was knocked down using siRNA and the tumor cells were then treated with oxaliplatin. The expression profile of 384 miRNAs was determined by TaqMan® human miRNA array and calculated by the ∆∆Ct method. Cellular viability was found to decrease after the treatment with oxaliplatin in a dose-dep...
Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Jasmine Evert, Surajit Pathak, Xiao-Feng Sun, Hong Zhang Tags: Research Paper Source Type: research

MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1.
In this study, we utilized microRNA microarray analysis and real-time PCR to verify that miR-93, miR-191, miR-137, miR-181 and miR-491-3p were significantly down-regulated and that miR-96, miR-21, miR-22, miR-15b and miR-92 were up-regulated in both HCT-15/OXA and SW480/OXA cell lines. Blocking miR-137 caused a significant inhibition of OXA-induced cytotoxicity, therefore, miR-137 was chosen for further research. An in vitro cell viability assay showed that knockdown of miR-137 in HCT-15 and SW480 cells caused a marked inhibition of OXA-induced cytotoxicity. Moreover, we found that miR-137 was involved in repression of YBX...
Source: Cancer Biomarkers - January 1, 2017 Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research

Silencing the livin gene enhances the cytotoxic effects of anticancer drugs on colon cancer cells.
CONCLUSION: siRNA-mediated down-regulation of livin gene expression could significantly suppress colon cancer growth and enhance the cytotoxic effects of anticancer drugs such as 5-FU and L-OHP. The results of this study suggest that silencing livin gene expression in combination with treatment with anticancer drugs might be a novel cancer therapy for colorectal cancer. PMID: 27904848 [PubMed - in process]
Source: Annals of Surgical Treatment and Research - December 3, 2016 Category: Surgery Tags: Ann Surg Treat Res Source Type: research

siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.
Authors: Montazami N, Kheir Andish M, Majidi J, Yousefi M, Yousefi B, Mohamadnejad L, Shanebandi D, Estiar MA, Khaze V, Mansoori B, Baghbani E, Baradaran B Abstract One of the most challenging aspects of colon cancer therapy is rapid acquisition of multidrug resistant phenotype. The multidrug resistance gene 1 (MDR1) product, p—glycoprotein (P—gp), pump out a variety of anticancer agents from the cell, giving rise to a general drug resistance against chemotherapeutic agents. The aim of this study was to investigate the effect of a specific MDR1 small interference RNA (siRNA) on sensitivity of ox...
Source: Cellular and Molecular Biology - December 2, 2015 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Identification of anti-metastatic drug and natural compound targets in isogenic colorectal cancer cells.
Abstract Therapeutic strategies for cancer treatment often remain challenging due to the cumulative risk derived from metastasis, which has been described as an aggressive state of cancer cell proliferation often resulting in failure of clinical therapy. In the current study, anti-metastatic properties of three chemotherapeutic drugs and three compounds from natural sources were investigated by comparative proteomic analysis. Proteomic profile comparison of the isogenic primary and metastatic colon cancer cell lines SW480 and SW620 identified two potential metastasis related molecular targets: fatty acid synthase ...
Source: Journal of Proteomics - October 23, 2014 Category: Biochemistry Authors: Lee JG, McKinney KQ, Pavlopoulos AJ, Park JH, Hwang S Tags: J Proteomics Source Type: research

Abstract 5382: A breakthrough in application of a drug delivery nanoparticle system for therapy and diagnosis of solid tumor
Conclusion: Our data suggest that sCA itself, while designed as an in vivo delivery device, can facilitate entrance of low molecular chemicals into tumor cells in vitro and in vivo. Citation Format: Xin Wu, Hirofumi Yamamoto, Mamoru Uemura, Taishi Hata, Junichi Nishimura, Ichiro Takemasa, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori. A breakthrough in application of a drug delivery nanoparticle system for therapy and diagnosis of solid tumor. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Wu, X., Yamamoto, H., Uemura, M., Hata, T., Nishimura, J., Takemasa, I., Mizushima, T., Doki, Y., Mori, M. Tags: Cancer Chemistry Source Type: research

Oxaliplatin activates the KEAP1/NRF2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.
Abstract Oxaliplatin is an important drug in the treatment of advanced metastatic colorectal cancer. NF-E2 P45-related factor 2 (NRF2) is a key transcription factor that controls genes encoding cytoprotective and detoxifying enzymes through antioxidant response elements (AREs) in their regulatory regions. Here, we report that oxaliplatin is an activator of the NRF2 signaling pathway, with up-regulation of ARE-driven genes and glutathione elevation. An injection of oxaliplatin into mice enhanced the expression of glutathione transferases and antioxidant enzymes in the small and large intestines of wild-type (WT) mi...
Source: Free Radical Biology and Medicine - February 17, 2014 Category: Biology Authors: Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin A, Li X, Wu J, Tang X Tags: Free Radic Biol Med Source Type: research